NEWPORT NEWS, Va., Sept. 4 On the heels of the recentpress release from the Mayo Clinic regarding molecular breast imaging,researchers from Thomas Jefferson University Hospital have released theirfindings using this new imaging modality at the American Society of ClinicalOncology national meeting.
Dr. Kristin Brill and her colleagues conducted a multi-center studycontaining 201 women who required additional imaging after a questionablemammogram. Patients had both breast MRI and molecular breast imaging. Theauthors concluded, "BSGI (Breast-Specific Gamma Imaging) demonstrates equalsensitivity to breast MRI in the detection of malignant and high-risk breastlesions while reducing the rate of indeterminate findings by 50 percent. BSGIhas additional advantages over MRI in that the study generates four to eightimages, as compared to up to 1000 images in MRI and can be utilized in allpatients including those with ferromagnetic implants or renal insufficiency.In addition, BSGI is conducted at a fraction of the cost per procedure ofbreast MRI."
The term BSGI has been used to describe molecular breast imaging for thelast 5 years. This imaging technology is FDA approved, is currently availablein approximately 80 centers across the United States and approximately 50,000patients have been imaged to date.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical imaging products tomarket. Dilon's cornerstone product, the Dilon 6800, is a high-resolution,small field-of-view gamma camera, optimized to perform Breast-Specific GammaImaging (BSGI), a molecular breast imaging procedure which images themetabolic activity of breast lesions through radiotracer uptake. Many leadingmedical centers around the country are now offering BSGI to their patients,including: Cornell University Medical Center, New York; George WashingtonUniversity Medical Center, Washington, D.C.; and The Rose, Houston. For moreinformation on Dilon Technologies please visit http://www.dilon.com.
SOURCE Dilon Technologies